Human herpesvirus 8 (HHV-8) or Kaposi's sarcoma associated herpesvirus (KSHV) is associated with Kaposi's sarcoma and primary effusion lymphoma. In vivo, HHV-8 DNA and transcripts have been detected in B cells, endothelial cells, macrophages, and epithelial cells. HHV-8 infects a variety of cell lines of human and animal origin, leading to latent or abortive infection. This study shows that the broad cellular tropism of HHV-8 may be in part due to its interaction with the ubiquitous host cell surface molecule, heparan sulfate (HS). This conclusion is based on the following findings: (i) HHV-8 infection of human foreskin fibroblast (HFF) cells was inhibited in a dose-dependent manner by soluble heparin, a glycosaminoglycan closely related to HS. Chondroitin sulfates A and C did not inhibit HHV-8 infection. (ii) Enzymatic removal of HFF cell surface HS with heparinase I and III reduced HHV-8 infection. (iii) Soluble heparin inhibited the binding of radiolabeled HHV-8 to human B cell lines, embryonic kidney epithelial (293) cells, and HFF cells, suggesting interference at the virus attachment stage. (iv) Cell surface adsorbed HHV-8 was displaced by soluble heparin. (v) Radiolabeled HHV-8 also bound to wild-type HS expressing Chinese hamster ovary (CHO-K1) cells. In contrast, binding of virus to mutant CHO cells deficient in HS was significantly reduced. These data show that the ␥2 herpesvirus HHV-8, similar to some members of ␣, ␤, and ␥2 herpesviruses, adsorbs to cells by binding to cell surface HS-like moieties. Heparin did not completely prevent the binding and infectivity of HHV-8, suggesting that HHV-8 interactions with HS could be the first set of ligand-receptor interaction leading to the binding with one or more host cell receptors essential for the subsequent viral entry process.
INTRODUCTION
Human herpesvirus 8 (HHV-8) or Kaposi's sarcoma associated herpesvirus (KSHV) DNA has been detected in the Kaposi's sarcoma (KS) tissues from all epidemiologic forms of KS (Boshoff et al., 1995; Chang et al., 1994; Dubin et al., 1999; Schulz et al., 1998) . HHV-8 DNA has been also detected in body-cavity-based B-cell lymphomas (BCBL) and in the B cells of HIV-positive and HIVnegative individuals (Dubin et al., 1999; Schulz et al., 1998) . HHV-8 encodes for more than 80 ORFs. The designation of ORFs 1 to 75 is based on the similarity to herpesvirus saimiri (HVS) ORFs and the unique ORFs designated with the prefix K (Russo et al., 1996; . HHV-8 has counterparts to other herpesvirus glycoproteins such as glycoproteins gB (ORF 8), gH (ORF 22) , gM (ORF 39), and gL (ORF47). In addition to these conserved glycoproteins, K1 and K8.1 genes encode for glycoproteins unique for HHV-8 (Russo et al., 1996; Neipel et al., 1997; Chandran et al., 1998) .
In vivo, HHV-8 DNA and transcripts have been identi-fied in human B cells (Schulz et al., 1998) , macrophages (Blasig et al., 1997) , endothelial cells (Boshoff et al., 1995; Schulz et al., 1998) , and epithelial cells (Diamond et al., 1998) . HHV-8 has also been shown to infect a variety of cell types in vitro including human B, endothelial, epithelial, and fibroblast cells as well as owl monkey kidney and baby hamster kidney fibroblast cells (Blackbourn et al., 2000; Flore et al., 1998; Moses et al., 1999; Renne et al., 1998; Vieira et al., 2001) . However, a sustained productive HHV-8 infection has not yet been established and inoculation of these cells usually results in an abortive and/or latent infection (Blackbourn et al., 2000; Flore et al., 1998; Moses et al., 1999; Renne et al., 1998; Vieira et al., 2001) .
The initial virus-cell interaction by some members of ␣ herpesviruses [herpes simplex virus type1 (HSV-1); herpes simplex virus type 2 (HSV-2); pseudorabies virus (PRV); bovine herpesvirus type 1 (BHV-1)], ␤ herpesviruses [human cytomegalovirus (HCMV); human herpesvirus 7 (HHV-7) and ␥2 herpesvirus [bovine herpesvirus-4 (BHV-4)] herpesviruses involves the binding to the ubiquitous cell surface proteoglycan heparan sulfate (HS) (Compton et al.,1993; Liang et al., 1993; Mettenleiter et al., 1990; Neyts et al., 1992; Spear, 1993; Secchiero et al., 1997; Skrincosky et al., 2000; Vanderplasschen et al., 1993; WuDunn and Spear, 1989) . We hypothesized that HHV-8's broad cellular tropism may be in part due to 1 These authors contributed equally to this work. 2 To whom reprint requests should be addressed at Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7424. Fax: (913) 588-7295. E-mail: bchandra@kumc.edu.
interactions with one or more ubiquitous host cell surface molecules such as HS. This hypothesis was tested by examining the role of HS in the entry of HHV-8.
Incubation of HHV-8 with soluble heparin, a glycosaminoglycan (GAG) closely related to HS or the removal of cell surface HS by heparinase I and III, reduced HHV-8 infection. Heparin blocked the binding of [ 3 H]-thymidinelabeled HHV-8 to human B, epithelial, and fibroblast cells. HHV-8 binding was also detected with the HS expressing Chinese hamster ovary (CHO-K1) cells while only a low percentage of virus bound to CHO mutant cells deficient in HS. These data suggest that HHV-8 infection of target cells involves interaction with cell surface HS molecules.
RESULTS

Heparin prevents HHV-8 infection of HFF cells
Although HHV-8 has a broad in vivo cellular tropism, analysis of in vitro HHV-8 interaction with host cells and quantitation of infection has been hampered by the absence of a lytic replication cycle and a reliable plaque assay. In addition, infection is often abortive and only a low percentage of HHV-8 infected cells such as human endothelial and human foreskin fibroblast (HFF) cells retained the viral genome in a latent form (Blackbourn et al., 2000; Flore et al., 1998; Moses et al., 1999; Renne et al., 1998; Vieira et al., 2001) . To monitor the HHV-8 binding and entry process, BCBL-1 cells carrying a recombinant HHV-8 expressing the green fluorescent protein (GFP-HHV-8) was established (Vieira et al., 2001) . Stable GFP-BCBL-1 cells containing the recombinant DNA was easily monitored by fluorescence microscopy for the expression of GFP (Fig. 1A) . GFP-HHV-8 in the supernatant of TPA induced BCBL-GFP cells was concentrated and used as the inoculum for infection.
GFP-HHV-8 titer was estimated using HFF cell monolayers since infection in these cells can be readily monitored compared to suspension cultures of human B cells (Vieira et al., 2001) . Three days postinfection, GFP ex- . The construction GFP-HHV-8 and the establishment of GFP-BCBL-1 cells have been described elsewhere (Vieira et al., 2001) . Virus from culture supernatant from TPA-induced GFP-BCBL-1 cells was concentrated and served as the source of GFP-HHV-8 in the infection assays. (B) Expression of GFP in HFF cells 3 days postinfection with GFP-HHV-8 (magnification: 40ϫ). (C) Expression of HHV-8 latency associated nuclear antigen (LANA-1) ORF 73 protein in the nuclei of acetone-fixed HFF cells 5 days postinfection with GFP-HHV-8. The punctate nuclear fluorescence indicating ORF 73 protein (LANA-1) expression was detected by polyclonal rabbit anti-ORF 73 antibodies and anti-rabbit FITC antibodies (magnification: 160ϫ). (D) Nonreactivity of anti-ORF 73 antibodies with uninfected HFF cells (magnification: 160ϫ).
pressing cells in eight-well chamber slides were observed by fluorescence microscopy and enumerated ( Fig. 1B) . Infection with 50 l of GFP-HHV-8 stock virus resulted in approximately 250-280 of green fluorescent protein expressing cells per well. Similar to our earlier observation (Vieira et al., 2001) , infected HFF cells showed no cytopathic effect, and no lytic cycle associated protein expressions or infectious virus could be detected (data not shown). Only a latent infection was observed in the HFF cells as evidenced by the presence of circular HHV-8 representing latent DNA and by the expression of HHV-8 latency-associated nuclear antigen (LANA-1) encoded by ORF 73 gene (Vieira et al., 2001) . The earliest time point of LANA-1 detection by IFA was after 72 h. Even though the expression of GFP under the control of promiscuous elongation factor-1-␣-promoter was evident 1 day postinfection, the green fluorescence signals was weaker and difficult to quantitate. However, the intensity of fluorescence signals increased over time and were clearly evident after 3 days postinfection. Hence GFP-HHV-8 infection was assessed on day 3 postinfection. Since only a latent infection was observed in the HFF cells, the GFP expressing cells represent infection by the input virus and not due to reinfection by the spread of replicating viruses from the infected cells. We have previously shown that all HFF cells infected with GFP-HHV-8 expressed LANA-1 (Vieira et al., 2001) . After observing the slides for GFP expressions, cells were fixed with cold acetone and tested with polyclonal rabbit antibodies against LANA-1. Acetone fixation quenched the signals from GFP considerably and hence the punctate nuclear fluorescence representing LANA-1 was easily detected in the GFP expressing cells (Fig.  1C ). This confirmed that the expression of GFP serves as an indicator of HHV-8 entry and infection. Specificity of GFP-HHV-8 entry and infection was also verified by neutralization assays using sera from HIVϩKSϩ individuals and monoclonal and polyclonal antibodies against HHV-8 envelope glycoproteins (manuscript in preparation).
Heparin is closely related to HS and inhibition of virus infectivity by heparin treatment has been considered as an evidence for members of ␣, ␤, and ␥2 herpesviruses interaction with cell surface HS molecules (Compton et al.,1993; Liang et al., 1993; Mettenleiter et al., 1990; Neyts et al., 1992; Secchiero et al., 1997; Skrincosky et al., 2000; Spear, 1993; Vanderplasschen et al., 1993; WuDunn and Spear, 1989) . To determine whether HHV-8 interaction with target cells involves HS, the ability of soluble heparin to prevent GFP-HHV-8 infectivity was examined. A constant volume (50 l) of GFP-HHV-8 was incubated with different concentrations of heparin or chondroitin sulfates A and C for 90 min at 37°C and the mixtures were added to HFF cell monolayers. After incubation at 37°C for 2 h, cells were washed to remove unbound virus, heparin, and chondroitin sulfates, and incubated further for 3 days at 37°C. HHV-8 infection was assessed by counting the number of green fluorescent cells. Viability of the cells were not affected by heparin or chondroitin sulfates at the concentrations used (data not shown). Heparin inhibited GFP-HHV-8 infection in a dose-dependent manner with the inhibition ranging from 65 to 92% and reaching a plateau between 50 and 100 g/ml of heparin (Table 1) . Chondroitin sulfates A and C did not inhibit GFP-HHV-8 infection even at a concentration of 1000 g/ml. Similar results were also seen with 293 cells (data not shown). Since only a latent infection was observed in the HFF cells without the expression of lytic cycle proteins and infectious virus, inhibition of GFP expression suggested that heparin blocked the infection of input HHV-8 possibly by inhibiting the interaction of HHV-8 with cell surface HS-like molecules. The inability of heparin to completely prevent the infectivity of HHV-8 suggests that HHV-8 interaction with HS is probably the first set of ligand-receptor interaction leading to the binding with other host cell receptors essential for the subsequent viral entry process.
Removal of HFF cell HS by heparinase I and III lowered HHV-8 infection
Heparinase I and III cleave HS at different sites and liberate them from the cell surface (Stringer and Gallagher, 1997 ). Removal of cell surface HS-like molecules a 50 l of GFP-HHV-8 was incubated at 37°C for 90 min with DMEM alone or DMEM containing different concentrations of soluble heparin or chondroitin sulfate A or C (10, 50, 100, 500, and 1000 g/ml). This mixture was added to HFF cell monolayers in 8-well chamber slides and incubated for 2 h at 37°C. Cells were washed 3 times to remove virus, heparin, and chondroitin sulfates, and incubated with growth medium at 37°C. After 3 days, slides were examined by an inverted fluorescent microscope. Heparin or chondroitin sulfates did not affect the viability of the cells at the concentrations used.
b Green fluorescent cells ( Fig. 1B) indicative of GFP-HHV-8 entry were counted. After infection with 50 l of HHV8-GFP stock virus, approximately 250-280 green fluorescent-expressing HFF cells per well were detected. The average number of GFP-HHV-8 infected green fluorescent cells from three experiments are shown.
c Data presented represent the average Ϯ SD of three experiments. Chondroitin sulfate A and C did not inhibit GFP-HHV-8 infection even at a concentration of 1000 g/ml.
by heparinase I and III has been shown to reduce the infection of herpesvisuses (Shukla et al., 1999; Vanderplasschen et al., 1993) . To confirm the role of HS in HHV-8's interaction with cell surface HS-like molecules, HFF cells were first treated for 2 h with a mixture of heparinase I and III and the ability of GFP-HHV-8 to infect these cells were assessed. Heparinase I and III at the concentrations used did not show any detectable toxicity on HFF cells and the viability of the cells was not affected. GFP-HHV-8 infectivity was reduced by pretreating HFF cells with heparinase I and III (Table 2) . Maximum inhibition (68%) was seen with 4 unit/ml of heparinase I and III and the higher concentrations did not result in increased inhibition. The inability of heparinase I and III treatment to completely prevent the virus infection may be in part due to the lower efficiency of this method and also possibly due to binding of HHV-8 to other host cell surface molecules in the absence of HS. Nevertheless, these results also suggest an interaction between HHV-8 and cell surface HS-like molecules.
Heparin blocks HHV-8 binding to the host cells
In the infectious process of some members of ␣, ␤, and ␥2 herpesviruses, HS has been shown to be involved in the attachment stage of infection (Compton et al.,1993; Liang et al., 1993; Mettenleiter et al., 1990; Neyts et al., 1992; Spear, 1993; Secchiero et al., 1997; Skrincosky et al., 2000; Vanderplasschen et al., 1993; WuDunn and Spear, 1989) . To determine whether HS is involved in the initial stage of HHV-8 absorption to the host cells, we examined the ability of heparin to block the binding of [ 3 H]-thymidine-labeled HHV-8 to the cells. HHV-8 binding to cells was initially examined by electron microscopy (E17). [ 3 H]-thymidine-labeled virus was allowed to bind the untreated and paraformaldehyde-treated BJAB cells (HHV-8 negative B cells) at 37°C for 15 min, washed, and fixed with 2% glutaraldehyde. Thin sections were prepared and examined by transmission electron microscopy. After a 15-min incubation, herpesvirus particles bound to the surfaces of paraformaldehyde-treated (Figs. 2 A and 2B) and untreated (Figs. 2C, 2D, and 2E) cells were observed. Only enveloped virus particles were seen in these EM examinations indicating the specificity of labeled virus binding. We did not observe virus entry with paraformaldehyde-treated BJAB cells. In contrast, entry of virus was observed in unfixed BJAB cells (Figs. 2C-2F). Several virus particles in the process of binding and entering the cells via the endocytic vesicles were observed (Figs. 2C-2F).
To quantitate HHV-8 binding to its target cells, different concentrations (cpm) of purified [ 3 H]-thymidine-labeled HHV-8 were added to BJAB, BCBL-1, 293, and HFF cells and incubated at 37 or 4°C for 1 h. Cells were washed, precipitated with TCA, and measured for the cell associated radioactivity. We used the 0.1% paraformaldehydetreated cells, since this treatment allows the binding of virus but prevents the entry into cells and thus allows the performance of binding assays at 37°C (Miller and Hutt-Fletcher, 1988) . Labeled HHV-8 bound to BCBL-1, BJAB, 293, and HFF cells in a dose-dependent manner (Fig.  3A ). The maximum binding was observed with BCBL-1 cells which may be due the high concentration of HHV-8 receptors and/or high affinity receptors (Fig. 3A) . Similar results were also observed when HHV-8 binding assays were performed at 4°C with unfixed cells (data not shown). Dose-dependent HHV-8 binding was also detected with Raji, HeLa, Vero, BHK-21, and mouse L cells (data not shown).
To determine whether heparin inhibits HHV-8 binding, a constant quantity of purified labeled virus within the linear range of the dose-response curve (Fig. 3A) was mixed with medium alone or with different concentrations of heparin and incubated at 37°C for 1 h. These were then added to the paraformaldehyde-treated target cells, incubated at 37°C for 1 h, washed 5 times, precipitated with TCA, and counted. The cell-bound virus cpm in the presence or absence of heparin and the percentage inhibition of virus binding were calculated. Soluble heparin significantly inhibited the binding of labeled HHV-8 to all cell lines tested in a dose-dependent manner (Fig. 3B) . The percentage inhibition plateaued between 10 and 100 g/ml of heparin for all cell lines and the maximum inhibition ranged from 75 to 93%. Similar results were also observed when heparin treatment and binding assays were performed at 4°C with unfixed cells (data not shown). Specificity was shown by the absence of inhibition by chondroitin sulfates A and C even at a a Confluent monolayers of HFF cells in chamber slides were overlaid with different concentrations of heparinase I and III or PBS alone and incubated at 37°C for 2 h. The cells were washed and incubated with GFP-HHV-8 at 37°C. After 2-h incubation, cells were washed and incubated with growth medium at 37°C. At 3 days, green fluorescent cells, indicative of HHV-8 entry, were counted by an fluorescence microscope. Heparinase I and III at the concentrations used did not affect the viability of the cells.
b The average number of GFP-HHV-8-infected green fluorescent cells from three experiments are shown.
c Data presented represent the average Ϯ SD of three experiments.
concentration of 1000 g/ml (data not shown). Binding of [ 3 H]-thymidine-labeled ␥1 Epstein-Barr virus (EBV) to BJAB or Raji cells were not blocked by similar concentrations of heparin (data not shown). The inhibition of HHV-8 binding to target cells by heparin suggested that HHV-8 interacts with cell surface HS at the stage of absorption. The inability of heparin to completely prevent the virus binding suggests that HHV-8 must be also binding to other host cell molecules.
Displacement of cell surface adsorbed HHV-8 by heparin
To determine the specificity of HHV-8 interaction with cell surface HS and the inhibition by heparin, labeled virus was first allowed to adsorb to the paraformaldehyde-fixed HFF cells and at different times postabsorption, heparin was added to a final concentration of 10 g/ml. Cells were further incubated for a total period of 60 min at 37°C and the cell-associated radioactivity counted. Pretreatment of HFF cells with heparin did not affect HHV-8 binding and bound virus was not eluted with washes without heparin (data not shown). In contrast, when heparin was added to the virus-cell mixture, it was capable of displacing already adsorbed virus even when added 40 min after virus addition to the cells (Fig.  3C ). Specificity was shown by the absence of HHV-8 displacement by chondroitin sulfates even at a concentration of 1000 g/ml (data not shown). Reversal of HHV-8 binding to the cells by heparin not only demonstrated the specificity of HS interaction with HHV-8, but also confirmed that these interactions occur at an early stage of HHV-8 absorption to the host cells. The partial reversal of binding by the addition of heparin after 50 min of virus-cell interaction (Fig. 3C) suggested the possible onset of interactions between viral envelope glycoproteins and cellular receptors other than HS molecules.
HHV-8 binds to HS expressing CHO-K1 cell line but not to cells lacking HS
To verify the role of HS in the attachment of HHV-8 to the target cells, binding assays were done with wild-type CHO-K1 cell line expressing HS and its two mutant cell lines, pgsD-677 cells (deficient in HS but not chondroitin sulfate) and pgsA-745 cells (deficient in both HS and chondroitin sulfate) (Esko et al., 1985; Lidholt et al., 1992) . Radiolabeled HHV-8 bound readily to the CHO-K1 cells to the same extent as HFF and BJAB cells (Fig. 4) . In contrast, binding to the mutant cells was significantly impaired with only about 10% of HHV-8 binding to the pgsD-677 and pgsA-745 cells (Fig. 4) . These results confirmed the interaction of HHV-8 with the cell surface HS. The low percentage of HHV-8 binding to the cells lacking HS further supported the notion that HHV-8 also binds other host cell molecules.
DISCUSSION
Animal cell membranes are abundant with proteoglycans, which are made of a protein core with one or more covalently attached GAG chains that bind several different protein ligands (Kjellen and Lindhl, 1991; Rostand and Esko, 1997) . HS and other GAGs are present on the proteoglycans and expressed as integral membrane pro-teins, glycerol phosphatidyl inositol-linked membrane proteins, and proteins of extracellular matrices (Rostand and Esko, 1997; Stringer and Gallagher, 1997) . This anatomical feature of the cell membrane is exploited by viruses in their entry process. Interaction with HS as an initial step in the virus binding to the host cells was first described for the ␣-herpesvirus, HSV-1 (Spear, 1993) . Since then, PRV (␣-herpesvirus), BHV-1 (␣-herpesvirus), HCMV (␤-herpesvirus), HHV-7 (␤-herpesvirus), and BHV-4 (␥2-herpesvirus) have all been shown to interact specifically with cell surface HS (Compton et al.,1993; Liang et al., 1993; Mettenleiter et al., 1990; Neyts et al., 1992; Spear, 1993; Secchiero et al., 1997; Skrincosky et al., 2000; Vanderplasschen et al., 1993; WuDunn and Spear, 1989) . Viruses from other families, such as human immunodeficiency virus type 1 (HIV-1) (Roderiquez et al., preparation was mixed with medium alone or with different concentrations of heparin and incubated at 37°C for 1 h. These preparations were then added to the paraformaldehyde-treated target cells, incubated at 37°C for 1 h, washed 5 times, precipitated with TCA, and counted. The cell-associated virus cpm in the presence or absence of heparin and the percentage inhibition of virus binding were calculated. In the absence of heparin, approximately 29, 11, 15, and 18% of the input radioactivity became associated with the BCBL-1, BJAB, HFF, and 293 cells, respectively. Each reaction was done in triplicate and each point represents the average Ϯ SD of three experiments. (C) Displacement of adsorbed HHV-8 from the HFF cell surface by heparin. HFF cell monolayers treated with paraformaldehyde were incubated with labeled HHV-8 (1.2 ϫ 10 4 cpm). At the indicated times, monolayers were incubated with medium (controls) or with medium containing heparin (10 g/ml). Cells were further incubated for a total period of 60 min at 37°C, washed 5 times, precipitated with TCA, and counted. The cell-associated virus cpm in the presence or absence of heparin and the percentage inhibition of virus binding were calculated. Each reaction was done in triplicate and each point represents the average Ϯ SD of three experiments. In the absence of heparin, approximately 18% of the input radioactivity became associated with the HFF cells. 1995), vaccinia virus (Chung et al., 1998) , Sindbis virus (Byrnes and Griffin, 1998) , Dengue virus (Chen et al., 1997) , foot and mouth disease virus (Jackson et al., 1996) , respiratory syncytial virus (Feldman et al., 2000; Krusat and Streckert, 1997) , and adeno-associated virus (Summerford and Samulski, 1998) also bind the HS during their multistep virus entry process.
The ␥2-herpesvirus HHV-8 has a broad cellular tropism (Blackbourn et al., 2000; Blasig et al., 1997; Boshoff et al., 1995; Diamond et al., 1998; Dubin et al., 1999; Flore et al., 1998; Moses et al., 1999; Renne et al., 1998; Schulz et al., 1998; Vieira et al., 2001) . HHV-8 binds to a variety of cells and binding leads to entry in most of the cells as shown by the detection of HHV-8 DNA, limited HHV-8 gene expression and green fluorescent protein expression in human B cells, 293 cells, human endothelial cells, HFF cells, owl monkey kidney cells, BHK-21 cells, human bladder carcinoma, prostate carcinoma, lung carcinoma, and squamous carcinoma cells (Blackbourn et al., 2000; Flore et al., 1998; Moses et al., 1999; Renne et al., 1998; Vieira et al., 2001) . This broad tropism could be in part explained by the ability of HHV-8 to bind the ubiquitous cell surface HS molecule.
Our studies suggested that HS mediated binding of HHV-8 occur at an early stage of virus-cell interaction and is a reversible process. This resembles the sequence of events demonstrated for other herpesviruses, in which the interaction with cell surface HS is required to concentrate the virions on the cell surfaces and thus facilitating the virus binding to other cell surface receptors (Haywood, 1994; Spear, 1993) . The inhibition of HHV-8 binding to target cells by heparin suggested that HHV-8 interacts with cell surface HS at the stage of absorption. The inability of heparin to completely prevent the virus binding and infectivity of HHV-8 suggests that HHV-8 interactions with HS is probably the first set of ligand-receptor interactions leading to the binding with other host cell receptors essential for the subsequent viral entry process. These putative second receptors for HHV-8 interactions need to be identified.
Heparin at a concentration of 10 g/ml of heparin lowered the binding of [ 3 H]-thymidine-labeled HHV-8 to host cells by 80%. However, at least fivefold more concentration of heparin was needed to lower the HFF cells' infection of GFP-HHV-8 to the same extent and this may reflect the difference in the experimental systems used. Since the GFP-HHV-8 virus preparation contained both the wild-type and the recombinant virus (Vieira et al., 2001) , infection of cells were due to both population of viruses. Cell-associated cpm represented the binding of all virus populations labeled with [ 3 H]-thymidine, while GFP expression represented the infection by GFP-HHV-8 only. Hence, additional concentration of heparin required was probably to prevent the infection of both wild-type and GFP-HHV-8 population of viruses compared to the concentration required to inhibit the radiolabeled virus binding.
Inspection of the structure of heparin/heparan sulfate and sequence analysis of the heparin binding domain (HBD) of several proteins suggested that the negatively charged sulfate or carboxylate groups on heparin could interact via electrostatic interactions to positively charged residues in a protein or peptide (Cardin and Weintraub, 1989) . HBDs are enriched with positively charged basic amino acids (lysine, arginine, and histidine). Two typical HBDs (XBBXBX and XBBBXXBX) have been predicted, where B is a basic residue and X can be any other residue, but usually a hydrophobic residue (Cardin and Weintraub, 1989) . Predictive analysis of HHV-8 sequence revealed the presence of putative HBD in HHV-8 gB, gH, gM, and gpK8.1A (data not shown). The role of these glycoproteins in the interaction with HS is under investigation.
MATERIALS AND METHODS
Cells
HFF and 293 monolayer cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Grand Island, NY) with 2 mM glutamine, 10% fetal bovine serum (FBS), and antibiotics. CHO-K1 cells (ATCC-CCL-61) (Esko et al., 1985) , HS deficient CHO derivative pgsD-677 cells (ATCC-CRL-2244), HS, and chondroitin sulfate deficient CHO derivative pgsA-745 cells (ATCC-CRL-2242) (Lidholt et al., 1992) were grown in Ham's F12K medium (Gibco BRL) with 10% FBS and antibiotics. Suspension cultures of BCBL-1 cells (HHV-8 ϩ human B cells) (Renne et al., 1996) , recombinant green fluorescence protein-HHV-8 (GFP-HHV-8) harboring BCBL-1 cells (Vieira et al., 2001) , and BJAB cells (HHV-8 negative human B cells) were grown in RPMI 1640 medium with glutaMAX I (Gibco BRL) with 10% FBS and antibiotics. BCBL-1 cells contain about 40 copies of HHV-8 viral genome in a latent form and about 20% of the cells enter lytic cycle after induction with 12-O-tetradecanoylphorbol-13-acetate (TPA) (Sigma, St. Louis, MO) (Renne et al., 1996; Schulz et al., 1998) . Supernatant from TPA-induced BCBL-1 cells serve as the source of virus.
Recombinant HHV-8 expressing green fluorescence protein
The construction of recombinant HHV-8 expressing the green fluorescence protein has been described elsewhere (Vieira et al., 2001) . Briefly, a DNA fragment encoding green fluorescent protein (GFP) expressed by the promiscuous elongation factor-1-␣-promoter and the neomycin-resistant protein (Neo r ) expressed by the RSV promoter was inserted into the DraIII site in the 4.8-kb BamHI HHV-8 fragment (genomic position 83710). This fragment was electroporated into BCBL-1 cells and grown in medium containing G418 (Vieira et al., 2001) . Establishment of stable cells (GFP-BCBL-1) containing the recombinant DNA was easily monitored by fluorescence microscopy for the expression of GFP (Fig. 1A) .
GFP-HHV-8 in the supernatant of TPA-induced BCBL-GFP cells was concentrated as previously described (Vieira et al., 2001) and used as the inoculum for infection. Briefly, about 1500 ml of BCBL-1 cells grown to a density of 5 ϫ 10 5 /ml were induced with 20 ng/ml of TPA. On day 6, culture supernatant was centrifuged at 5000 g to remove the cells and cell debris. The virus was pelleted by centrifugation at 25,000 g for 90 min. Pellets were suspended in 1/250 original volume of medium, reclarified by centrifugation at 400 g at 4°C for 10 min 4 times, and filtered through 0.45-m membrane filters (Pall Corporation, Ann Arbor, MI). Aliquots were stored at Ϫ70°C.
GFP-HHV-8 infection and inhibition by heparin
GFP-HHV-8 (50 l) was incubated at 37°C for 90 min with DMEM alone or with DMEM containing different concentrations of soluble heparin and chondroitin sulfates A and C (10, 50, 100, 500, and 1000 g/ml). This mixture was added to HFF cell monolayers in eight-well chamber slides (Nagle Nunc International, Naperville, IL), incubated for 2 h at 37°C, washed 3 times to remove unbound virus, heparin, and chondroitin sulfates, and incubated with growth medium at 37°C. After 3 days, slides were examined by a Nikon Eclipse TE300 inverted fluorescent microscope. Green fluorescent cells (Fig. 1B) indicative of GFP-HHV-8 entry were counted using Nikon Magna firewire digital imaging system. After infection with 50l of HHV8-GFP stock virus, approximately 250-280 green fluorescent expressing HFF cells per well were detected.
After fluorescence microscopic observations, media from these slides were removed and dried, and cells were fixed with cold acetone for 10 min. Slides were tested in an indirect immunofluorescence assay with a polyclonal rabbit antibodies against LANA-1 ( Moses et al., 1999) . Briefly, fixed cells were incubated for 30 min at 37°C with prestandardized dilution of rabbit anti-ORF 73 IgG antibodies. After incubation, slides were washed rigorously in PBS and incubated further for 30 min at 37°C with a prestandardized dilution of fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG. After washing, slides were counterstained with 1:10,000 dilution of Evans blue (Sigma) for 5 min at room temperature, washed, and mounted with 50% (v/v) glycerol in PBS. Slides were examined under a fluorescence microscope.
Effect of HS removal by heparinase I and III on GFP-HHV-8 infection
Cell-surface HS removal by heparinase I and III was done as per methods described preciously (Shukla et al., 1999; Vanderplasschen et al., 1993) . Briefly, confluent monolayers of HFF cells in chamber slides were overlaid with different concentrations of heparinase I and III or PBS alone and incubated at 37°C for 2 h. The cells were washed and incubated with GFP-HHV-8 at 37°C. After a 2-h incubation, cells were washed and incubated with growth medium at 37°C. At 3 days, green fluorescent cells, indicative of HHV-8 entry, were counted by a fluorescence microscope. Heparinase I and III at the concentrations used did not have any detectable toxicity on HFF cells and the viability of the cells were not affected.
Radiolabeled HHV-8
[ 3 H]-thymidine HHV-8 in the TPA induced BCBL-1 cells supernatant was concentrated and purified as per procedure described previously (Lake and Hutt-Fletcher, 2000) . Briefly, about 1500 ml of BCBL-1 cells grown to a density of 5 ϫ 10 5 /ml were induced with TPA and added with 2 Ci/ml of [ 3 H]-thymidine (TRK61; specific activity: 851GBq/mmol; Amersham Pharmacia Biotech, Apiscataway, NJ). An additional 2 Ci/ml of [ 3 H]-thymidine was added 2 days later. Briefly, after 6 days post-TPA induction, culture supernatants were centrifuged at 5000 g at 4°C for 10 min to remove the cells and cell debris. Virus in the clarified supernatant was pelleted by centrifugation at 27,000 g at 4°C for 90 min. Pellets were resuspended in 1/500 original volume of RPMI 1640, reclarified by centrifugation at 400 g at 4°C for 10 min 4 times, and filtered through 0.45-m filters.
Concentrated virus was purified using Nycodenz (Sigma) as per the methods well established for the purification of EBV (Lake and Hutt-Fletcher, 2000) . Briefly, a 24-42% continuous gradient of Nycodenz (Sigma) in 1 mM potassium phosphate was made by layering 1 ml of 42, 40, 38, 36, 34, 32, 30, 28, 26 , and 24% Nycodenz in a centrifuge tube and allowing the steps to diffuse overnight at 4°C. Then, 500 l of concentrated virus was layered on top of the gradient and centrifuged in a Beckman SW41 Ti rotor at 70,000 g for 2 h at 4°C (Lake and Hutt-Fletcher, 2000) . Fractions (0.5 ml) were collected from the top. The refractive index was measured with 25-l aliquots. Aliquots (10 l) were spotted on filters, dried, untreated or precipitated with tricholoroacetic acid (TCA), and counted. Fractions were dialyzed against phosphate-buffered saline to remove Nycodenz and were tested for binding with cells as described below. Virus collected from the 28-30% interface contained the enveloped viruses and showed the maximum cell binding activities. Purity of the virus was also measured by electron microscopy and Western blots with Mabs against HHV-8 virion envelope associated gpK8.1A and nonstructural ORF 59 proteins Zhu et al., 1999) .
Radiolabeled HHV-8 binding assays
Cells grown at log phase (viability Ͼ 90%) were untreated or briefly treated with ice-cold 0.1% paraformaldehyde (Miller and Hutt-Fletcher, 1988; Lake and Hutt-Fletcher, 2000) and used for binding assays. Untreated and paraformaldehyde-fixed cells were washed 3 times with RPMI 1640 containing 5% FBS. Used for each reaction were 1 ϫ 10 6 BJAB or BCBL cells. Purified [ 3 H]thymidine-labeled HHV-8 was added to the cell pellets, mixed, and incubated for 1 h at 4°C for unfixed cells or at 37°C for paraformaldehyde-fixed cells. After incubation, cells were washed 5 times with RPMI 1640 containing 5% FBS, spotted on filters, radioactivity precipitated with TCA, and counted. HFF, 293 cells, CHO-K1 cells, or its mutant derivative cells (pgsD-677 and pgsA-745) in 24well plates were used for binding assays. After incubation with the virus, cells were washed 5 times, lysed with 1% SDS and 1% Triton X-100, radioactivity precipitated with TCA, and counted. All experiments were done in triplicate and repeated 3 times.
Inhibition of radiolabeled HHV-8 binding by heparin
A constant quantity of purified [ 3 H]-thymidine-labeled virus preparation in RPMI 1640 with 5% FBS was mixed with different concentrations of soluble heparin (Sigma) and incubated at 37°C for 1 h. These mixtures were then added to unfixed or 0.1% paraformaldehyde-treated 1 ϫ 10 6 BJAB cells (per reaction) or to HFF and 293 cells, and incubated further at 4 or 37°C for 1 h. Cells were washed 5 times with RPMI 1640 containing 5% FBS, radioactivity precipitated with TCA, and counted.
For testing the ability of heparin to displace the bound HHV-8, a constant quantity of labeled virus was added to 0.1% paraformaldehyde-fixed HFF cells. At different time points, heparin was added to a final concentration of 10 g/ml. Cells were further incubated for a total period of 60 min at 37°C and processed as above. All experiments were done in triplicate and repeated 3 times.
